Treatment of M93‐047 NRAS‐mutant xenografts with vehicle, BETi (JQ‐1 or OTX‐015), MEKi (PD901), or BETi plus MEKi, demonstrated that BETi/MEKi combinations led to sustained tumor growth inhibition compared to single agents (Fig 3C and D, and Appendix Table S2). This evidence concerns the gene NRAS and neoplasm.